Table 1. IGF-1R expression by HRS cells in relation to disease parameters, EBV status and treatment.
| Characteristic | IGF1R+ (n = 44, 55%) | IGF1R- (n = 36, 45%) | p-value |
| Median age (range) | 25 (7–83) | 35 (8–69) | 0.14* |
| Gender | 0.53† | ||
| - male | 24 (55%) | 19 (53%) | |
| - female | 20 (45%) | 17 (47%) | |
| Histology subtype | 0.02† | ||
| - NS | 38 (86%) | 23 (64%) | |
| - MC | 1 (2%) | 8 (22%) | |
| - LR | 1 (2%) | - | |
| - cHL, NOS | 4 (9%) | 5 (14%) | |
| Ann Arbor Stage | 0.93† | ||
| - I-II | 27 (61%) | 21 (58%) | |
| - III-IV | 15 (34%) | 14 (39%) | |
| - n.a. | 2 (5%) | 1 (3%) | |
| EBV status | 0.36† | ||
| - positive | 11 (25%) | 12 (33%) | |
| - negative | 33 (75%) | 23 (64%) | |
| - n.a. | - | 1 (3%) | |
| B-symptoms | 0.83† | ||
| -present | 25 (57%) | 19 (53%) | |
| -absent | 17 (39%) | 16 (44%) | |
| -n.a. | 2 (5%) | 1 (3%) | |
| IPS | 0.67† | ||
| -low (0-2) | 28 (64%) | 22 (61%) | |
| -high (≥3) | 9 (21%) | 10 (28%) | |
| -n.a. | 7 (16%) | 4 (11%) | |
| Chemotherapy | 0.71† | ||
| -ABVD | 20 (45%) | 22 (61%) | |
| -BEACOPP | 1 (2%) | 1 (3%) | |
| -MOPP/ABVD | 7 (16%) | 5(14%) | |
| -Pediatric protocols | 12 (27%) | 6 (17%) | |
| -RT alone | 2 (5%) | 1 (3%) | |
| -n.a. | 2 (5%) | 1 (3%) |
NS: nodular sclerosis; MC: mixed cellularity; LR: lymphocyte rich; LD: lymphocyte depleted; NOS: not otherwise specified; n.a. = not available; *Mann-Whitney test; †Pearson's chi-squared test.